Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma (NCT05826535)
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Who can join: Review the eligibility criteria below.
Location: University of California-Irvine Medical Center — Irvine, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (35 Sites)
Showing the first 25 of 35 sites.
- University of California-Irvine Medical Center — Irvine, California
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California, Los Angeles (UCLA) Medical Center — Los Angeles, California
- Scripps Clinic — San Diego, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Medstar Georgetown University Hospital — Washington D.C., District of Columbia
- Augusta University Medical Center — Augusta, Georgia
- Indiana Blood and Marrow Transplantation — Indianapolis, Indiana
- University of Iowa — Iowa City, Iowa
- University of Louisville Brown Cancer Center — Louisville, Kentucky
- Louisiana State University Health Sciences Center — Shreveport, Louisiana
- Corewell Health — Grand Rapids, Michigan
- University of Nebraska Medical Center — Omaha, Nebraska
- John Theurer Cancer Center Hackensack University Medical Center — Hackensack, New Jersey
- University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico
- Roswell Park Comprehensive Cancer Center — Buffalo, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Atrium Health Wake Forest Baptist — Winston-Salem, North Carolina
- University of Cincinnati (UC) Physicians Company, LLC — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Lehigh Valley Topper Cancer Center Institute — Allentown, Pennsylvania
- Thomas Jefferson University — Philadelphia, Pennsylvania
- West Penn Hospital — Pittsburgh, Pennsylvania
- Vanderbilt University Medical Center — Nashville, Tennessee
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Relapsed Non-Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.